Sartorius Biotech Inks PER.C6 Licensing Deal

June 21, 2007
BioPharm International Editors

Royal DSM NV (Heerlen, the Netherlands, www.dsm.com) and Dutch biotechnology company Crucell NV (Leiden, the Netherlands, www.crucell.com) have announced a nonexclusive PER.C6 research licensing deal with Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com).

Royal DSM NV (Heerlen, the Netherlands, www.dsm.com) and Dutch biotechnology company Crucell NV (Leiden, the Netherlands, www.crucell.com) have announced a nonexclusive PER.C6 research licensing deal with Sartorius Biotech GmbH (Goettingen, Germany, www.sartorius.com).

Sartorius will use Crucell’s key technology to evaluate MAbs produced using PER.C6 cells for calibrating and testing equipment products useful in the manufacture and purification of recombinant MAbs. Crucell and Sartorius further agreed to expand their PER.C6 collaboration by sharing technology and data on antibody production. Financial details were not disclosed.

Related Content:

News